Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma

Immunotherapies have altered the treatment paradigm in HCC. Surrogate and modified endpoints are used to assess early success in clinical studies and guide clinical practice. We sought to determine whether surrogate endpoints and modifications to the conventional criteria for tumor response (RECIST)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2023-12, Vol.78 (6), p.1755-1762
Hauptverfasser:	Lim, Mir, Muquith, Maishara, Miramontes, Bernadette, Lee, Chieh-Ju, Espinoza, Magdalena, Huang, Yi-Hsiang, Hsiehchen, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - pathology Cross-Sectional Studies Humans Immunotherapy Liver Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!